Zuellig Pharma China

What Zuellig Pharma China does

Zuellig Pharma China is the China operations of Zuellig Pharma, Asia's largest integrated pharmaceutical distribution and healthcare solutions company. The business distributes pharmaceutical, consumer healthcare, vaccine, medical device, animal health, and specialty care products to hospitals, clinics, pharmacies, and other healthcare channels, complemented by market access and regulatory affairs services for pharmaceutical manufacturers and clinical trial logistics for global CROs. Within China, operations are anchored by a regional headquarters in Beijing and a clinical depot in the Shunyi District of Shanghai, feeding into the parent's 18-market, 71-warehouse Asia-Pacific footprint that reaches 200,000+ customers including 22,000 hospitals, 55,000 clinics, and 90,000 pharmacies.

The technology stack centers on the eZRx+ B2B eCommerce platform for ordering and fulfillment, complemented by eZTracker (blockchain supply chain traceability), eZTender (tender and contract management), eZCooler (passive 2-8°C cold chain), and PatientCare+ (rare disease, immuno-oncology, and chronic condition patient support). Clinical trial supply is operated through the Clinical Reach network (26+ depots across 60+ markets) and recently automated via Hai Robotics' HaiPick System 1 at the South Korea CTS Innovation Center, which supports ambient, cold, frozen, deep frozen, and cryogenic temperature zones. GxP, GDP, GMP, and ISO 9001 certifications underpin a quality framework recognized through EcoVadis Platinum and CDP A-List 2024 awards.

Revenue is generated through three streams: (1) contract-based pharmaceutical distribution services generating transaction fees on storage, logistics, and last-mile delivery; (2) brand commercialization and acquisition of established consumer healthcare brands such as Zam-Buk, Vapex, Propan, and now Cialis rights, monetized via OTC sales and royalties; and (3) market access solutions including regulatory support, market entry, and commercial execution for pharma manufacturers, billed as professional services. Pricing is quote-based and negotiated under multi-year contracts. The GTM motion combines a 2,500+ rep direct enterprise field sales force with the eZRx+ digital channel. The Zuellig family retains majority control, with a minority stake held by Singapore sovereign wealth fund Temasek Holdings (since 2007).

Name

Zuellig Pharma China

Legal name

Zuellig Pharma Pte Ltd

Website

https://zuelligpharma.com

Company type

Private

Founded year

1922

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Zuellig Pharma China distributes pharmaceutical, consumer healthcare, and clinical trial supplies across China as part of Asia-Pacific's largest integrated healthcare solutions company, serving hospitals, clinics, and pharmacies via an eZRx+ B2B platform and 71 regional warehouses.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution Services

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)

akta.pro secondary industries

Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Pharmaceutical & Life Sciences Cold Chain Storage (2–8°C / CRT) (TLALABAF), Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD)

Keywords

• Pharmaceutical distribution
• Healthcare logistics
• Clinical trial support
• Cold chain storage
• Pharmaceutical commercialization

Headquarters

HQ city

Wanchai

HQ country

China

HQ region

Asia

Offices19 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Infrastructure, Personnel, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Distribution Services: Core distribution services for pharmaceutical products including storage, logistics, and last-mile delivery to healthcare facilities
2. Brand Acquisitions: Acquisition and distribution of established consumer healthcare brands such as Zam-Buk, Vapex, and Propan
3. Market Access Solutions: Helping pharmaceutical manufacturers access Asian markets through regulatory support, market entry, and commercial execution

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels1 record

Core offering

Zuellig Pharma China distributes pharmaceutical, medical device, consumer healthcare, vaccine, animal health, and specialty care products to hospitals, clinics, and pharmacies across Asia-Pacific. The company operates a network of 71 warehouses with multi-zone temperature-controlled storage, runs a direct sales force of 2,500+ representatives, and supports the full pharmaceutical value chain through its B2B eCommerce platform (eZRx+), clinical trial logistics services, and commercialization/market access solutions.

Differentiator

Problem solved

Functional benefit

Brands

• eZRx+: ASEAN's largest B2B healthcare eCommerce platform for ordering pharmaceutical products
• eZTracker
• eZTender
• eZCooler
• PatientCare+
• EZ Rx
• Clinical Reach

Products and services

• eZRx+ B2B eCommerce platform enabling healthcare providers to order pharmaceutical and healthcare products online with order visibility, analytics, and digital fulfillment integration.
• eZTracker

Quantifiable outcome

• 200,000+ healthcare facilities served across Asia-Pacific
• +2 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered major, core and minor.

• Bayer Consumer Care AGmajorStrategic or Co-development Partner · 1 January 2023Acquisition of Zam-Buk and Vapex consumer healthcare brands from Bayer, expanding Zuellig's portfolio of over-the-counter products across Asia-Pacific markets
• Eli Lilly and CompanymajorStrategic or Co-development PartnerStrategic partnership including acquisition of Cialis rights and distribution of Mounjaro (tirzepatide) in Asia-Pacific markets
• LundbeckcoreStrategic or Co-development PartnerExpanded partnership for neuro-psychiatric health solutions distribution across Asia-Pacific markets
• OrganoncoreStrategic or Co-development PartnerPartnership for women's health solutions distribution in Myanmar, expanding women's health portfolio
• ADP Pharma CorporationminorStrategic or Co-development PartnerAcquisition of Propan brand, expanding consumer healthcare product portfolio
• Hai RoboticscoreTechnology or IntegrationPartnership for clinical trial logistics automation, implementing automated storage and retrieval systems for clinical trial supplies

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Regional players

• Yusen Logistics: Japan-headquartered global logistics provider with significant healthcare and pharmaceutical logistics capabilities across Asia-Pacific. Comparable in temperature-controlled distribution infrastructure but as a logistics specialist rather than full-service pharmaceutical distributor.

Broad incumbents

• Walgreens Boots Alliance: Global pharmacy-led, health and wellbeing retail and wholesale company. Comparable in the integrated pharma distribution plus retail/wholesale pharmacy model, though predominantly US/Europe rather than Asia.
• Cardinal Health: US-based Fortune 500 pharmaceutical distributor and medical products company. Operates similar wholesale distribution and specialty services model as Zuellig but predominantly serves North American customers.
• McKesson Corporation: Largest pharmaceutical distributor globally, operating a multinational wholesale and specialty distribution platform. Comparable in core pharmaceutical distribution model but with global rather than Asia-focused footprint and broader product portfolio.
• AmerisourceBergen (Cencora): Global pharmaceutical distribution and consulting services company formed from AmerisourceBergen. Closely aligned with Zuellig's distribution-plus-services model at much larger scale and global reach.

Direct peers

• Sinopharm Group: China's largest pharmaceutical distributor and state-owned enterprise, operating the dominant drug distribution network across mainland China. Direct competitor in the China market and comparable at scale in pharmaceutical wholesale and cold chain logistics.
• DKSH Holding: Swiss-headquartered market expansion services group specializing in pharmaceutical and consumer goods distribution across Asia-Pacific. Most direct comparable given overlapping Asia footprint, healthcare distribution focus, and similar agency/commercialization service model.
• Shanghai Pharmaceuticals Holding: Major state-owned pharmaceutical manufacturer and distributor in China with both manufacturing and distribution operations. Directly comparable in pharmaceutical wholesale distribution across Chinese and select APAC markets.
• China Resources Pharmaceutical Group: Hong Kong-listed pharmaceutical distributor and manufacturer under China Resources Holdings, with extensive distribution network in mainland China and select APAC markets. Comparable in scale, business model, and regional product mix.

Emerging players

• CEVA Logistics: Global third-party logistics provider (CMA CGM subsidiary) with growing healthcare and pharmaceutical logistics capabilities in Asia. Partial overlap with Zuellig's contract logistics and cold chain offerings, focused on transportation rather than full-service distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/zuellig-pharma_2
• Xx.com/zuellighealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zuellig Pharma China